Intranasal Nanoemulsions for Direct Nose-to-Brain Delivery of Actives for CNS Disorders

Shiv Bahadur, Dinesh M Pardhi, Jarkko Rautio, Jessica M Rosenholm, Kamla Pathak

Forskningsoutput: TidskriftsbidragÖversiktsartikelPeer review

57 Citeringar (Scopus)


The treatment of various central nervous system (CNS) diseases has been challenging, despite the rapid development of several novel treatment approaches. The blood–brain barrier (BBB) is one of the major issues in the treatment of CNS diseases, having major role in the protection of the brain but simultaneously constituting the main limiting hurdle for drugs targeting the brain. Nasal drug delivery has gained significant interest for brain targeting over the past decades, wherein the drug is directly delivered to the brain by the trigeminal and olfactory pathway. Various novel and promising formulation approaches have been explored for drug targeting to the brain by nasal administration. Nanoemulsions have the potential to avoid problems, including low solubility, poor bioavailability, slow onset of action, and enzymatic degradation. The present review highlights research scenarios of nanoemulsions for nose-to-brain delivery for the management of CNS ailments classified on the basis of brain disorders and further identifies the areas that remain unexplored. The significance of the total dose delivered to the target region, biodistribution studies, and long-term toxicity studies have been identified as the key areas of future research.
Sidor (från-till)1-27
Antal sidor27
StatusPublicerad - 18 dec. 2020
MoE-publikationstypA2 Granska artikel i en vetenskaplig tidskrift


Fördjupa i forskningsämnen för ”Intranasal Nanoemulsions for Direct Nose-to-Brain Delivery of Actives for CNS Disorders”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här